Baxter International Inc. (NYSE:BAX) will begin trading ex-dividend on December 3, 2020. The quarterly dividend payment of $ 0.245 per share is scheduled to be paid on January 4, 2021. The dividend yield based on the latest trading day closing price was 1.30 percent. To secure the dividend payout, investors must buy the stock prior to the ex-dividend date of December 3, 2020.
Dividends History
wpDataTable with provided ID not found!Click Here For More Historical Dividends Of Baxter International Inc.
Baxter International Inc. recently reported third quarter financial results on October 29, 2020, before market open, the Deerfield based company announced income for the third quarter of $ 0.83 per share, from the revenue of $ 2,972.00 million. The quarterly earnings enlarged 16.90 percent while revenues improved 4.24 percent compared with the same quarter last year.
Street analysts expected Baxter International Inc. recently reported third quarter financial results on October 29, 2020, before market open, the Deerfield based company to report income of $ 0.73 per share on revenue of $ 2832.28 million for the third quarter. The bottom line results beat street analysts by $ 0.1 or 13.70 percent, at the same time, top line results outshined analysts by $ 139.72 million or 4.93 percent.
Stock Performance
Shares of Baxter International Inc. traded low $ -0.56 or -0.74 percent on Tuesday, reaching $ 75.51 with volume of 2.60 million shares. Baxter International Inc. has traded high as $ 77.09 and has cracked $ 75.40 on the downward trend
According to the previous trading day, closing price of $ 75.51, representing a 10.09 % increase from the 52 week low of $ 69.10 and a 20.09 % decrease over the 52 week high of $ 95.19.
The company has a market capital of $ 38.57 billion and is part of the Healthcare sector and Medical Instruments & Supplies industry.
Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies.
